国泰中证生物医药ETF联接A(006756)利润分配表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 收入 |
-156,695,818.15 |
-199,017,814.37 |
-39,439,431.90 |
-65,953,777.45 |
| 利息合计 |
149,798.98 |
81,609.56 |
223,253.26 |
116,533.25 |
| 其中：存款利息收入 |
149,798.98 |
81,609.56 |
223,253.26 |
116,533.25 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-50,901,107.07 |
-20,766,172.37 |
-23,666,172.61 |
-16,798,608.39 |
| 其中：股票投资收益 |
46,998.96 |
7,268.52 |
558,386.17 |
354,941.38 |
| 基金投资收益 |
-50,935,996.68 |
-20,805,871.72 |
-24,224,558.78 |
-17,153,549.77 |
| 债券投资收益 |
-36,199.11 |
2,738.63 |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
24,089.76 |
29,692.20 |
- |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-106,397,481.59 |
-178,529,276.01 |
-16,431,748.63 |
-49,494,546.32 |
| 其他收入 |
452,971.53 |
196,024.45 |
435,236.08 |
222,844.01 |
| 费用 |
1,834,502.26 |
976,642.47 |
2,316,081.85 |
1,156,670.90 |
| 管理人报酬 |
208,390.42 |
110,414.92 |
301,255.20 |
156,151.43 |
| 基金托管费 |
41,678.06 |
22,082.94 |
60,251.08 |
31,230.29 |
| 销售服务费 |
1,426,253.78 |
741,105.87 |
1,747,193.90 |
866,356.98 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
158,180.00 |
103,038.74 |
207,381.67 |
102,932.20 |
| 利润总额 |
-158,530,320.41 |
-199,994,456.84 |
-41,755,513.75 |
-67,110,448.35 |
微信公众号
证券之星APP
基本资料
